Explore the potential role of the inflammatory tumor microenvironment in resistance to melanoma therapy in this peer-reviewed article from Melanoma Management.
Browsing: immune response
A preclincal human-derived antibody has been demonstrated to preferentially attack cancer cells, rather than healthy tissue by targeting an immune evasion mechanism.
Prostate cancer relapse may be attributed to the use of common nonsurgical androgen deprivation therapies, study suggests.
An experimental PI3Kδ-targeting agent has entered a Phase II trial to determine whether it can boost the antitumor immune response in head and neck squamous cell carcinoma.
The impact of dendritic cell–tumor fusion cells on cancer vaccines – past progress and future strategies
Explore the field of breakthrough immunotherapies further by reading about the impact of dendritic cell–tumor fusion cells on cancer vaccines in this peer-reviewed article from Immunotherapy.
A new study has demonstrated that the DNAM-1 receptor stimulates NK cell-mediated cancer cell elimination and highlights competing receptor TIGIT as a potential therapeutic target.
A new study has highlighted a potential method of targeting the metabolic pathway in order to boost the anticancer activity of T cells.
Death ligands and granulysin: mechanisms of tumor cell death induction and therapeutic opportunities
This review details the mechanisms behind death ligand- and granulysin-mediated cancer cell deaths – processes activated by natural killer cells and cytotoxic T lymphocytes in order to control tumor development during immune surveillance.
Mounting evidence suggests that regulatory T cells have an increased presence in cancer settings. Find out more about what prompts Treg-cell accumulation within tumor microenvironment, what cues are necessary, what they regulate, and how they may be tackled for therapeutic purposes.
Investigational synthetic vaccine proven to eliminate precancerous cervical lesions in almost half of the women involved in a small clinical trial.